Journal: Pharmaceutics
Article Title: Efficacy and Safety of a Brain-Penetrant Biologic TNF-α Inhibitor in Aged APP/PS1 Mice
doi: 10.3390/pharmaceutics14102200
Figure Lengend Snippet: Effect of TfRMAb-TNFR on BBB tight-junction proteins and brain inflammation. Chronic TfRMAb-TNFR dosing in aged APP/PS1 mice significantly increased ZO-1 ( a ) and claudin-5 ( b ) compared to the saline-treated mice measured using Western blotting of the cerebrum homogenates. Both TfRMAb-TNFR and etanercept increased I ĸ Bα in the cerebrum homogenates compared to the saline-treated mice ( c ). Data are presented as mean ± SD of n = 4–9 per treatment group, and data were analyzed using the one-way ANOVA with the Holm Sidak’s post hoc test. * p < 0.05 and ** p < 0.01 for the indicated comparisons.
Article Snippet: Membranes were probed at 4 °C overnight with anti-mouse zonula occludens-1 (ZO-1) rabbit polyclonal antibody (1:1000 in 3% milk, Thermo Fisher Scientific, Waltham, MA, USA), anti-human amyloid precursor protein (APP) mouse monoclonal antibody (1:1000 in 3% milk, BioLegend, San Diego, CA, USA), anti-claudin-5 mouse monoclonal antibody (1:1000 in 3% milk, Santa Cruz Biotechnology, Dallas, TX, USA), anti-β-site APP cleaving enzyme 1 (BACE1) rabbit polyclonal antibody (1:1000 in 3% milk, Thermo Fisher Scientific, Waltham, MA, USA), anti-IκBα mouse monoclonal antibody (1:1000 in 3% milk, Cell Signaling Technology, Danvers, MA, USA), anti-TfR-1 mouse monoclonal antibody (1:1000 in 3% milk, Thermo Fisher Scientific, Waltham, MA, USA), anti-TfR-2 mouse monoclonal antibody (1:1000 in 3% milk, Thermo Fisher Scientific, Waltham, MA, USA) and anti-ferroportin rabbit polyclonal antibody (1:1000 in 3% milk, Novus Biologicals, Centennial, CO, USA).
Techniques: Saline, Western Blot